nach oben

Clinical and Translational Oncology

Erschienen in:

19.01.2021 | Research Article

Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population

verfasst von: K. Holub, G. Louvel

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Due to a steadily growing use of stereotactic radiotherapy (SRT) for treatment of brain metastases (BMs), the in-field failure after an initial stereotaxy is an increasingly frequent problem. Repeat stereotactic radiotherapy (re-SRT) shows encouraging results in terms of local control. However, the evidence on prognostic factors limiting the overall survival (OS) of re-treated patients is scarce. Here, we sought to analyze the patients’ and treatment characteristics influencing the survival outcomes after re-SRT.

Methods

Data of all patients with local failure of initial SRT treated from 2012 to 2019 were retrospectively reviewed and cases treated with salvage SRT were analyzed. We analyzed the impact of patients’ and treatment characteristics on overall survival after re-SRT by Kaplan–Meier method and Cox regression models. Local and distant brain control, cause of death, and radionecrosis rate were also assessed.

Results

Forty-seven patients with 55 BMs treated with re-SRT were evaluated. Median OS after re-SRT was 9.2 months and the overall local control was 83.6%. Nine BMs (16.4%) presented local relapse (LR), 12 (21.8%) radionecrosis, while 21 patients (44.7%) developed new BMs. Only absence of extracranial metastases at BMs diagnosis (HR 0.42, CI 95%; 0.18–0.97), extracranial disease progression (HR 2.39, CI 95%; 1.06–5.38) and distant brain failure (HR 3.94, CI 95%; 1.68–9.24) after re-SRT were significantly associated with patients’ survival. Extracranial progression following re-SRT was an independent prognosticator of worse OS.

Conclusion

Re-SRT after LR presented excellent local control with acceptable RN rate and improved patients’ survival, limited mainly by extracranial and distant brain progression.

Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27–42. https://doi.org/10.1016/B978-0-12-811161-1.00002-5.CrossRefPubMed

Barbour AB, Jacobs CD, Williamson H, et al. Brain metastases treated with radiosurgery or radiation therapy practice patterns for brain metastases in the United States in the stereotactic radiosurgery era. Adv Radiat Oncol. 2019;5(1):43–52. https://doi.org/10.1016/j.adro.2019.07.012.CrossRefPubMedPubMedCentral

Sallabanda M, García-Berrocal MI, Romero J, et al. Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival. Clin Transl Oncol. 2020;22:1809–17. https://doi.org/10.1007/s12094-020-02321-x.CrossRefPubMed

Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21. https://doi.org/10.1093/neuonc/nox077.CrossRefPubMedPubMedCentral

Cacho-Díaz B, Spínola-Maroño H, González-Aguilar A, et al. Factors associated with long-term survival in central nervous system metastases. J Neurooncol. 2018;140:159–64. https://doi.org/10.1007/s11060-018-2946-x.CrossRefPubMed

Nieder C, Mehta MP, Geinitz H, Grosu AL. Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms. Crit Rev Oncol Hematol. 2018;126:13–8. https://doi.org/10.1016/j.critrevonc.2018.03.018.CrossRefPubMed

Kurtz G, Zadeh G, Gingras-Hill G, et al. Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection. Int J Radiat Oncol Biol Phys. 2014;88(1):137–42. https://doi.org/10.1016/j.ijrobp.2013.10.003.CrossRefPubMed

Nguyen MN, Noel G, Antoni D. La réirradiation des métastases cérébrales : revue des cinq dernières années [Reirradiation of brain metastasis: Review of the last five years]. Cancer Radiother. 2019;23(6–7):531–40. https://doi.org/10.1016/j.canrad.2019.07.144.CrossRefPubMed

Chidambaram S, Pannullo SC, Schwartz TH, et al. Reirradiation of recurrent brain metastases: where do we stand? World Neurosurg. 2019;125:156–63. https://doi.org/10.1016/j.wneu.2019.01.182.CrossRefPubMed

10.

Gogineni E, Vargo JA, Glaser SM, et al. Long-term survivorship following stereotactic radiosurgery alone for brain metastases: risk of intracranial failure and implications for surveillance and counseling. Neurosurgery. 2018;83:203–9. https://doi.org/10.1093/neuros/nyx376.CrossRefPubMed

11.

Nieder C, Yobuta R, Adler JR. Second re-irradiation of brain metastases: a review of studies involving stereotactic radiosurgery. Cureus. 2018;10(12):e3712. https://doi.org/10.7759/cureus.3712.CrossRefPubMedPubMedCentral

12.

Nieder C. Second re-irradiation: a delicate balance between safety and efficacy. Phys Med. 2019;58:155–8. https://doi.org/10.1016/j.ejmp.2019.01.004.CrossRefPubMed

13.

Bilger A, Bretzinger E, Fennell J, et al. Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Med. 2018;7:2350–9. https://doi.org/10.1002/cam4.1486.CrossRefPubMedPubMedCentral

14.

Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;6:48. https://doi.org/10.1186/1748-717X-6-48.CrossRefPubMedPubMedCentral

15.

Ayala-Peacock DN, Attia A, Braunstein SE, et al. Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. J Neurooncol. 2017;135(2):403–11. https://doi.org/10.1007/s11060-017-2588-4.CrossRefPubMedPubMedCentral

16.

Balermpas P, Stera S, von der Müller Grün J, et al. Repeated in-field radiosurgery for locally recurrent brain metastases: feasibility, results and survival in a heavily treated patient cohort. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0198692.CrossRefPubMedPubMedCentral

17.

Kim IY, Jung S, Jung TY, et al. Repeat stereotactic radiosurgery for recurred metastatic brain tumors. J Korean Neurosurg Soc. 2018;61:633–9. https://doi.org/10.3340/jkns.2017.0238.CrossRefPubMedPubMedCentral

18.

Koffer P, Chan J, Rava P, et al. Repeat stereotactic radiosurgery for locally recurrent brain metastases. World Neurosurg. 2017;104:589–93. https://doi.org/10.1016/j.wneu.2017.04.103.CrossRefPubMed

19.

Dincoglan F, Sager O, Demiral S, et al. Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. Indian J Cancer. 2019;56(2):151–6. https://doi.org/10.4103/ijc.IJC_786_18.CrossRefPubMed

20.

Chen JC, Petrovich Z, Giannotta SL, Yu C, Apuzzo ML. Radiosurgical salvage therapy for patients presenting with recurrence of metastatic disease to the brain. Neurosurgery. 2000;46(4):860–7. https://doi.org/10.1097/00006123-200004000-00017.CrossRefPubMed

21.

McKay WH, McTyre ER, Okoukoni C, et al. Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery. J Neurosurg. 2017;127:148–56. https://doi.org/10.3171/2016.5.JNS153051.CrossRefPubMed

22.

Rana N, Pendyala P, Cleary RK, et al. Long-term outcomes after salvage stereotactic radiosurgery (SRS) following in-field failure of initial SRS for brain metastases. Front Oncol. 2017;7:279. https://doi.org/10.3389/fonc.2017.00279.CrossRefPubMedPubMedCentral

23.

Greto D, Livi L, Bonomo P, et al. Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience. Radiol Med. 2014;119(9):721–6. https://doi.org/10.1007/s11547-014-0383-2.CrossRefPubMed

24.

Moreau J, Khalil T, Dupic G, et al. Second course of stereotactic radiosurgery for locally recurrent brain metastases: safety and efficacy. PLoS ONE. 2018. https://doi.org/10.1371/journal.pone.0195608.CrossRefPubMedPubMedCentral

25.

Loi M, Caini S, Scoccianti S, et al. Stereotactic reirradiation for local failure of brain metastases following previous radiosurgery: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;153:103043. https://doi.org/10.1016/j.critrevonc.2020.103043.CrossRefPubMed

26.

Holt DE, Gill BS, Clump DA, et al. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol. 2015;5:84. https://doi.org/10.3389/fonc.2015.00084.CrossRefPubMedPubMedCentral

27.

Iorio-Morin C, Mercure-Cyr R, Figueiredo G, et al. Repeat stereotactic radiosurgery for the management of locally recurrent brain metastases. J Neurooncol. 2019;145(3):551–9. https://doi.org/10.1007/s11060-019-03323-8.CrossRefPubMed

28.

Maranzano E, Trippa F, Casale M, et al. Reirradiation of brain metastases with radiosurgery. Radiother Oncol. 2012;102:192–7. https://doi.org/10.1016/j.radonc.2011.07.018.CrossRefPubMed

29.

Jiang X, Wang H, Song Y, et al. A second course of stereotactic image-guided robotic radiosurgery for patients with cerebral metastasis. World Neurosurg. 2019;123:e621–8. https://doi.org/10.1016/j.wneu.2018.11.238.CrossRefPubMed

30.

Skeie BS, Skeie GO, Enger PØ, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 2011;75(5–6):684–91. https://doi.org/10.1016/j.wneu.2010.12.054 (PMID: 21704936).CrossRefPubMed

Titel: Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population
verfasst von: K. Holub
G. Louvel
Publikationsdatum: 19.01.2021
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 7/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02544-y

Springer Medizin

Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population

Abstract

Objectives

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus

Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling

Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients

Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs

Recommended procedures and responsibilities for radiosurgery (SRS) and extracranial stereotactic body radiotherapy (SBRT): report of the SEOR in collaboration with the SEFM

Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie